COMP <GO>
ABBV vs NVS // ENTERPRISE SCALE & MARKET CAP
AbbVie Inc. (NYSE) VS. Novartis AG (NYSE) • 15-METRIC TALLY: ABBV 7
— NVS 6
▲ ENTERPRISE SCALE & MARKET CAP LEADER: ABBV
LAST: $294.89 (+1.41%) • MKT CAP: $513.86B
market-cap
$513.86B
LAST: $160.79 (-0.19%) • MKT CAP: $307.40B
market-cap
$307.40B
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ABBV VS. NVS)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ABBV | NVS | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 70.20% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 29.00% | 9.90% | +19.10 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation | 33.3x | 21.0x | +12.30 | NVS | /valuation <GO> |
| Free Cash Flow Yield | 3.47% | 2.21% | +1.26 | ABBV | /fcf-yield <GO> |
| Operating Margin | 24.60% | 13.90% | +10.70 | ABBV | /operating-margins <GO> |
| Net Profit Margin | 6.90% | 10.90% | -4.00 | NVS | /net-margins <GO> |
| Revenue Growth (YoY) | 8.60% | 15.40% | -6.80 | NVS | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 2.27% | 0.00% | +2.27 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 5.33 | 3.74 | +1.59 | ABBV | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 8/9 | -1.00 | NVS | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 65.1 | 69.1 | -4.00 | NVS | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.15 | 1.05 | +0.10 | ABBV | /macro-sensitivity <GO> |
| Forward P/E Multiple | 113.1x | 27.6x | +85.50 | NVS | /forward-pe <GO> |
| Enterprise Scale & Market Cap ACTIVE | $513.86B | $307.40B | $206.46B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ABBV REV | NVS REV | ABBV GROSS % | NVS GROSS % | ABBV FCF | NVS FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $61.16B | — | 70.2% | — | $17.82B | — |
| FY 2024 | $56.33B | — | 70.0% | — | $17.83B | — |
| FY 2023 | $54.32B | — | — | — | $20.39B | — |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ABBV // BETA 1.15
NVS // BETA 1.05